Kinaset Therapeutics, a newly-founded biopharmaceutical company, has raised a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv.

Kinaset Therapeutics intends to develop novel therapeutics that can positively impact people affected by intractable diseases, including severe asthma. The firm's novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma with a group of dedicated drug development experts working to bring the therapy forward.